The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register

BACKGROUND: Data of real clinical practice in diabetes mellitus (DM) register allow to evaluate features and trends in structure of glucose-lowering therapy (GLT). AIM: Тo analyze of structure of GLT received by patients with type 2 diabetes mellitus (T2DM) in Moscow region for 2018 and to evaluate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inna V. Misnikova, Yulia A. Kovaleva, Mikhail А. Isakov, Alexander V. Dreval
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2019
Materias:	type 2 diabetes mellitus the structure of glucose-lowering therapy the diabetes mellitus register Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/439d315ae2c34ab9923cb2fe0d394fd4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:439d315ae2c34ab9923cb2fe0d394fd4
record_format	dspace
spelling	oai:doaj.org-article:439d315ae2c34ab9923cb2fe0d394fd42021-11-14T09:00:22ZThe glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register2072-03512072-037810.14341/DM10084https://doaj.org/article/439d315ae2c34ab9923cb2fe0d394fd42019-08-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/10084https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378BACKGROUND: Data of real clinical practice in diabetes mellitus (DM) register allow to evaluate features and trends in structure of glucose-lowering therapy (GLT). AIM: Тo analyze of structure of GLT received by patients with type 2 diabetes mellitus (T2DM) in Moscow region for 2018 and to evaluate its dynamics over 15 years. METHODS: Analysis of GLT structure was carried out on basis of data from register of patients with DM in Moscow region, which is part of National register of diabetes mellitus in Russian Federation. In March 2018 it contained data on 211,792 T2DM patients of Moscow region. Structure of GLT administration was evaluated according T2DM duration, patient’s age and presence of cardiovascular diseases (CVD). Dynamics of GLT is analyzed from 2004 to 2018 yrs. RESULTS: In 2018 non-insulin glucose-lowering drugs (NIGD) prescription prevailed (78.3%), insulin therapy was prescribed in 18.5% of patients, 3.2% of patients did not receive drug therapy. Most commonly prescribed NIGD were metformin (69.3%) and sulfonylurea (51.3%). Older patients more often than younger did not use GLT at all and less frequently received insulin therapy and iDPP-4. Insulin therapy was prescribed twice as often in patients with CVD compared with patients without CVD (29.6% and 15.5%). NIGD monotherapy has been less commonly used in patients with CVD (67.3% and 81.2%). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) were prescribed to patients with CVD GLP-1 RA – in 0.1% of cases, without CVD in 0.3% of cases, and sodium-glucose cotransporter 2 (SGLT2) inhibitors in 1.1% and 0.6%. correspondently. CONCLUSION: Metformin was most commonly prescribed drug in GLT structure for T2DM patients in the Moscow region in 2018 yr. Percentage of new drugs in the structure of GLT increased mainly due to iDPP-4, and secondly due to SGLT2 inhibitors. New classes of GLT were more often prescribed to patients of younger age, with diabetes duration up to 10 years, overweight or obese. Administration of NIGD with proven cardiovascular protection in presence of CVD is almost two times less than for those without CVD.Inna V. MisnikovaYulia A. KovalevaMikhail А. IsakovAlexander V. DrevalEndocrinology Research Centrearticletype 2 diabetes mellitusthe structure of glucose-lowering therapythe diabetes mellitus registerNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 3, Pp 206-216 (2019)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus the structure of glucose-lowering therapy the diabetes mellitus register Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus the structure of glucose-lowering therapy the diabetes mellitus register Nutritional diseases. Deficiency diseases RC620-627 Inna V. Misnikova Yulia A. Kovaleva Mikhail А. Isakov Alexander V. Dreval The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
description	BACKGROUND: Data of real clinical practice in diabetes mellitus (DM) register allow to evaluate features and trends in structure of glucose-lowering therapy (GLT). AIM: Тo analyze of structure of GLT received by patients with type 2 diabetes mellitus (T2DM) in Moscow region for 2018 and to evaluate its dynamics over 15 years. METHODS: Analysis of GLT structure was carried out on basis of data from register of patients with DM in Moscow region, which is part of National register of diabetes mellitus in Russian Federation. In March 2018 it contained data on 211,792 T2DM patients of Moscow region. Structure of GLT administration was evaluated according T2DM duration, patient’s age and presence of cardiovascular diseases (CVD). Dynamics of GLT is analyzed from 2004 to 2018 yrs. RESULTS: In 2018 non-insulin glucose-lowering drugs (NIGD) prescription prevailed (78.3%), insulin therapy was prescribed in 18.5% of patients, 3.2% of patients did not receive drug therapy. Most commonly prescribed NIGD were metformin (69.3%) and sulfonylurea (51.3%). Older patients more often than younger did not use GLT at all and less frequently received insulin therapy and iDPP-4. Insulin therapy was prescribed twice as often in patients with CVD compared with patients without CVD (29.6% and 15.5%). NIGD monotherapy has been less commonly used in patients with CVD (67.3% and 81.2%). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) were prescribed to patients with CVD GLP-1 RA – in 0.1% of cases, without CVD in 0.3% of cases, and sodium-glucose cotransporter 2 (SGLT2) inhibitors in 1.1% and 0.6%. correspondently. CONCLUSION: Metformin was most commonly prescribed drug in GLT structure for T2DM patients in the Moscow region in 2018 yr. Percentage of new drugs in the structure of GLT increased mainly due to iDPP-4, and secondly due to SGLT2 inhibitors. New classes of GLT were more often prescribed to patients of younger age, with diabetes duration up to 10 years, overweight or obese. Administration of NIGD with proven cardiovascular protection in presence of CVD is almost two times less than for those without CVD.
format	article
author	Inna V. Misnikova Yulia A. Kovaleva Mikhail А. Isakov Alexander V. Dreval
author_facet	Inna V. Misnikova Yulia A. Kovaleva Mikhail А. Isakov Alexander V. Dreval
author_sort	Inna V. Misnikova
title	The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
title_short	The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
title_full	The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
title_fullStr	The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
title_full_unstemmed	The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
title_sort	glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the moscow region register
publisher	Endocrinology Research Centre
publishDate	2019
url	https://doaj.org/article/439d315ae2c34ab9923cb2fe0d394fd4
work_keys_str_mv	AT innavmisnikova theglucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT yuliaakovaleva theglucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT mikhailaisakov theglucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT alexandervdreval theglucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT innavmisnikova glucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT yuliaakovaleva glucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT mikhailaisakov glucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister AT alexandervdreval glucoseloweringtherapystructureinspecialgroupsoftype2diabetesmellituspatientsbasedondatafromthemoscowregionregister
_version_	1718429521789583360

The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register

Ejemplares similares